SOURCE: FutureWorld Corp

FutureWorld Corp

June 02, 2016 08:00 ET

FutureWorld (FWDG) Bioceutical Sciences Takes Its First Step Into Pharmaceutical Space

Company Appoints Well Renowned Scientist as the COO & CSO for Drug Target Discovery & New Drug Applications

SAINT PETERSBURG, FL --(Marketwired - June 02, 2016) - FutureWorld Corp (OTC PINK: FWDG), a cannabis technology accelerator and a leading provider of advanced technologies and solutions to the global cannabis industry, announces today that on May 20, 2016, the Company has elected Dr. Bobban Subhadra as the Chief Technology and Operation Officer of its subsidiary, Bioceutical Sciences, effective June 1, 2016. Dr. Bobban Subhadra core expertise is in drug target discovery and new drug applications for various indications. He works with early-stage biotech companies to develop and commercialize core platform technologies.

Dr. Subhadra has conducted his doctoral studies in Microbiology and Immunology at School of Medicine, University of New Mexico. After graduating he studied the role of neuroserpin, tissue plasminogen activator, and thyroid hormone in synaptic plasticity and Alzheimer's disease in mouse models. He has published extensively in prestigious journals including Nature, Science, and Neurochemistry International. With his core expertise in immunology and biochemistry and with 10+ years of industry R & D experience, he has developed numerous patented technologies and products for biochemical, biofuel, and pharmaceutical companies. More recently, as the Director of R & D at Quorum Innovations, he developed and commercialized numerous microbiome technologies.

Dr. Bobban Subhadra and his team at Bioceutical Sciences will focus on the creation of pharmaceutic drugs with multiple technologies incorporated as a drug delivery system such as hydrophobic, a nano-particle surrounded by a hydrophilic Nano-capsule much like liposomal but with improved efficiency for cellular integration using specifically formulated antigens. Potential theoretical applications are neuropathic pain, esophagitis, and immune enhancement. With the completion of the method of delivery technology for this current drug, Bioceutical Sciences' primary research team can effectively focus on technology for the drug's application and the drug's future classification.

The Company is in the process of filing multiple patents in the next few weeks.

FutureWorld is preparing Bioceutical Sciences for the ensuing spin-off.

About FutureWorld Corp.

FutureWorld (OTC PINK: FWDG), a Delaware corporation, is a leading provider of advanced technologies and solutions to the global cannabis industry. FutureWorld, together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of cannabis related products and services, such as industrial Hemp. FutureWorld, through its subsidiaries, provides personal and professional THC and CBD test kits, pharmaceutical grade CBD oil solutions, SafeVape vaporizers, smart sensor technology, communication network, surveillance security, data analysis for smart cultivation and consultation for the industrial hemp and legal medicinal cannabis. Our wireless agricultural smart sensor networks offer precision to the agriculture, irrigation systems, and greenhouses for the global cannabis and hemp industry. FutureWorld and its subsidiaries do not grow, distribute or sell marijuana.

As the only Cannabis Technology Accelerator, FutureWorld will incubate and fund leading technologies, products, and services for the cannabis industry (Industrial Hemp) for the foreseeable future, bringing value to its core and its shareholders.

To request further information about FutureWorld, please email us at info@futureworldcorp.com, log onto our website at http://www.futureworldcorp.com or visit us at our Facebook page facebook.com/futureworldcorp or on Twitter @futureworldinc.

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact Information